known about the role of this receptor during viral infection. In this study, we show that 23 sIL6R but not IL6 is induced by viral infection via the cyclooxygenase-2 pathway. The COX-2 expression plasmid pCMV-COX-2 has been preciously described (30). 131 pHBV-1.3 (adw) was generated from the HBV genome as described previously (31). All observed as in A549 cells (Fig. 1A) and primary human alveolar type cells (Fig. 1B) .
254
These data suggest significant expression of sIL6R was induced by IAV infection.
255
To clarify the mechanism of sIL6R production, we use a shedding inhibitor to block COX-2 knockdown inhibited sIL6R expression at both the mRNA and protein levels (Fig.   293   2D ). Prostaglandin E2, the main metabolite of COX-2, also induced sIL6R mRNA 294 expression in a dose-and time-dependent manner in PBMCs (Fig. 2E and F over-expression had no effect on IL6 mRNA or protein levels, suggesting that this 304 enzyme is likely not involved in regulating IL6 expression in these cells (Fig. 3A) .
305
Furthermore, to explore whether IL6 expression influences that of sIL6R, we examined 306 sIL6R mRNA and protein levels in A549 cells treated with varying concentrations of 307 rhIL6 protein for 24h (Fig. 3B ). In addition, we measured sIL6R levels in A549 cells 308 treated with 40 ng/ml rhIL6 protein for varying time points (Fig. 3C) increased the mRNA and protein levels each IFNα effector examined ( Fig. 5D and E).
377
sIL6R also increased the mRNA levels of IFNα receptor IFNAR1 in A549 cells (Fig. 5F ). sIL6R-mediated antiviral function via p28.
382
We confirm that sIL6R acts independent with IL6. Since it has been reported that IL6R 383 can also bind to CNTF (11), p28 (14) and gp130, here we further investigated whether 384 these three cellular factors play a role in sIL6R-mediated antiviral function. (Fig. 6D) . The results showed that none of them can be affected by 395 rhsIL6R.
396
We next investigated whether sIL6R exert antiviral function via any of the three factors.
397
Specific siRNA (si-p28, si-CNTF, si-gp130) or nonsense control siRNA were synthesized 398 for the following antiviral assays, and their silencing efficacies were confirmed at the 399 RNA level (Fig. 6E) . Each specific siRNA was co-transfected into A549 cells along with 400 pCMV-sIL6R and then infected with VSV-eGFP for 4 h before flow cytometry analysis 401 (Fig. 6F) . The results showed that eGFP expression was reduced after overexpression of 402 sIL6R and that this reduction could be partly restored after silence of the p28 by si-p28. pCMV-sIL6R were co-transfected into A549 cells and then infected with IAV (MOI=1).
405
The results showed that IAV replication was reduced after overexpression of sIL6R and 406 the reduction was restored by si-p28 as well (Fig. 6G) . The silence of p28 by si-p28 could 407 restore the antiviral effect of sIL6R in time-and dose-dependent manner (Fig. 6H, I ).
408
Taken together, sIL6R mediated antiviral activity, at least in part, through p28 pathway. cytosolic levels decreased over time in the sIL6R-transfected cells (Fig. 7A ). Similar 418 results were obtained with immunofluorescence assays 48 h after transfection (Fig. 7B-D) .
419
These results are consistent with the increased production of type I IFNs observed. Based on these results, we propose a hypothetical model for the role of sIL6R in 525 virus-triggered induction of type I IFN during the antiviral immune response (Fig. 8B ). In 
